Leaflet RIGEVIDON 21+7 0.030mg / 0.150mg sugar-coated tablets


Indicated for: contraception

Route of administration: oral

Substance: ethinylestradiol + levonorgestrel (estrogen + progestogen)

ATC: G03AA07 (Genito urinary system and sex hormones | Hormonal contraceptives for systemic use | Progestogens and estrogens, fixed combinations)

Ethinylestradiol and levonorgestrel are a combination of hormones commonly used in oral contraceptives. This medication prevents pregnancy by inhibiting ovulation, altering cervical mucus, and changing the uterine lining so that sperm cannot fertilize the egg.

It is taken daily, usually at the same time, according to the instructions on the blister pack. It is important not to miss any dose to maintain contraceptive effectiveness.

Side effects may include nausea, headaches, changes in the menstrual cycle, breast tenderness, or, rarely, allergic reactions and an increased risk of thrombosis. Smoking and age over 35 can increase the risk of serious side effects.

The combination of ethinylestradiol and levonorgestrel is effective for preventing pregnancy, but its use should be supervised by a doctor, especially if there are risk factors or other medical conditions.

General data about RIGEVIDON 21+7 0.030mg / 0.150mg

  • Substance: ethinylestradiol + levonorgestrel
  • Date of last drug list: 01-05-2026
  • Commercial code: W01969001
  • Concentration: 0.030mg / 0.150mg
  • Pharmaceutical form: sugar-coated tablets
  • Quantity: 21
  • Product type: generic
  • Price: 10.51 RON
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: GEDEON RICHTER PLC. - UNGARIA
  • Holder: GEDEON RICHTER PLC. - UNGARIA
  • Number: 556/2008/01
  • Shelf life: 3 years